Ramucirumab in the treatment of gastric cancer

04/2020

MUDr. Lukáš Chlachula

Onkologické oddělení, Nemocnice Nový Jičín

SUMMARY

Gastric cancer is one of the malignancies in the Czech Republic with a declining incidence over time and is the third most common cause of death from oncological diagnosis worldwide. The most common histological subtype is adenocarcinoma. The treatment of gastric adenocarcinomas is always complex, including surgery, chemotherapy, radiotherapy and targeted therapy. Ramucirumab is a monoclonal antibody against vascular endothelial growth factor receptor 2 (VEGFR-2), which blocks the binding of a specific ligand, thereby preventing signal transduction and triggering a signaling pathway leading to tumor neoangiogenesis. Efficacy has been described in two studies - RAINBOW and REGARD.

Key words

gastric adenocarcinoma, targeted therapy, ramucirumab, VEGF, VEGFR